Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | TPH1 | P17752 | 3/20 | 0.58 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43862 | 1.00 | GRB2 (0.76) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| SCHEMBL148122 | 1.00 | GRB2 (0.76) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL4364332 | 0.98 | GRB2 (0.73) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL16289248 | 0.98 | GRB2 (0.73) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL29399075 | 0.98 | GRB2 (0.73) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| Dl-Phenylalanine SCHEMBL28313877 | 0.95 | SLC7A5 (0.71) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| SCHEMBL28901130 | 0.94 | GRB2 (0.68) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| SCHEMBL28901132 | 0.94 | GRB2 (0.68) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| SCHEMBL13205275 | 0.92 | GRB2 (0.66) | GRB2PTPN1SLC7A5PTGS1ALPI | |
| SCHEMBL21803821 | 0.91 | GRB2 (0.64) | GRB2PTPN1SLC7A5PTGS1ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1832 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| CN-118812647-A | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2024-10-22 | — | — | CN | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| CN-113481228-B | Microbial unnatural amino acid introducing system and construction method | 中国药科大学 | 2024-07-19 | — | — | CN | claimed |
| CN-118317615-A | Hole transport layer and preparation method and application thereof | 广东脉络能源科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2012125973-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2012-09-20 | — | — | WO | claimed |
| CN-102442921-A | 15N/19Preparation method of F double-labeled unnatural amino acid and intermediate thereof | USTC UNIV SCIENCE TECH CN | 2012-05-09 | — | — | CN | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| US-7053214-B2 | β-sheet mimetics and composition and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| US-6943157-B2 | Reverse-turn mimetics and composition and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2005-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | GRB2 1612/4885PTPN1 2752/4885SLC7A5 258/4885 |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | GRB2 783/4885PTPN1 1761/4885SLC7A5 2440/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | GRB2 1920/4885PTPN1 1969/4885SLC7A5 576/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | GRB2 750/4885PTPN1 709/4885SLC7A5 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.